Related Experiment Video

Updated: Jan 10, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

537

A Bibliometric Analysis of Drug Resistance in Pediatric Acute Lymphoblastic Leukemia

Alireza Khanahmad1,2, Mohammad Hossein Khazaee-Nasirabadi3, Mahshid Lotfi4

  • 1Student Research Committee, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

Advanced Biomedical Research
|November 27, 2025
PubMed

Insights

Drug resistance in pediatric acute lymphoblastic leukemia (ALL) is a significant challenge. This bibliometric analysis maps global research trends, identifying key biological mechanisms and therapeutic agents for future study.

Area of Science:

  • Hematology
  • Oncology
  • Pediatric Medicine

Background:

  • Drug resistance remains a critical obstacle in treating acute lymphoblastic leukemia (ALL), despite therapeutic advancements.
  • Pediatric ALL presents unique challenges in overcoming treatment resistance.
  • Understanding global research trends is crucial for addressing pediatric ALL drug resistance.

Purpose of the Study:

  • To provide a comprehensive bibliometric overview of global research on drug resistance in pediatric ALL.
  • To identify emerging research directions and key contributors in the field.
  • To highlight significant biological mechanisms and therapeutic agents related to pediatric ALL drug resistance.

Main Methods:

  • Bibliometric analysis of papers from the Web of Science Core Collection.
  • Keywords such as 'acute lymphoblastic leukemia,' 'pediatric,' and 'drug resistance' were utilized.
  • Data visualization and analysis were performed using Biblioshiny and VOSviewer.

Main Results:

  • Analysis of 432 original and 94 review articles from 48 countries.
  • The United States led in publications (148 articles) and citations (9569).
  • Key research themes included altered glucocorticoid response, P-gp overexpression, microRNA roles, and specific agents like clofarabine and nelarabine.

Conclusions:

  • Research on pediatric ALL drug resistance is multifaceted, attracting significant global attention.
  • This bibliometric analysis maps the current research landscape and identifies critical areas for future investigation.
  • Further research is needed on the clinical applications and resistance mechanisms of agents like clofarabine, nelarabine, daunorubicin, vincristine, and microRNA.
Abstract

Keywords:
Bibliometricsdrug resistanceneoplasmprecursor cell lymphoblastic leukemia-lymphoma

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K
Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
195
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
244
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
231